Phase I study of lapatinib (L) and temozolomide (T) combination for the treatment of progressive brain metastases (BM) in HER2-positive metastatic breast cancer patients (Pts) (LAPTEM, LAP 111172).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 570-570 ◽  
Author(s):  
E. De Azambuja ◽  
M. Lemort ◽  
J. R. Rossari ◽  
C. Moulin ◽  
A. Buttice ◽  
...  
2016 ◽  
Vol 16 (2) ◽  
pp. 82-86 ◽  
Author(s):  
Winston W. Tan ◽  
Jacob B. Allred ◽  
Alvaro Moreno-Aspitia ◽  
Donald W. Northfelt ◽  
James N. Ingle ◽  
...  

2019 ◽  
Vol 39 (12) ◽  
pp. 6903-6907 ◽  
Author(s):  
DAISUKE OTA ◽  
SOTARO AKATSUKA ◽  
TSUNEHIRO NISHI ◽  
TAKAO KATO ◽  
MASASHI TAKEUCHI ◽  
...  

Breast Cancer ◽  
2014 ◽  
Vol 22 (5) ◽  
pp. 503-509 ◽  
Author(s):  
Muhammet Ali Kaplan ◽  
Hamza Ertugrul ◽  
Ugur Firat ◽  
Mehmet Kucukoner ◽  
Ali İnal ◽  
...  

2010 ◽  
Vol 1 (1) ◽  
pp. 45-49
Author(s):  
AKIHIKO OSAKI ◽  
SHOSHU MITSUYAMA ◽  
JUN-ICHI KUREBAYASHI ◽  
HIROSHI SONOO ◽  
REIKI NISHIMURA ◽  
...  

Breast Cancer ◽  
2021 ◽  
Author(s):  
Takamichi Yokoe ◽  
Sasagu Kurozumi ◽  
Kazuki Nozawa ◽  
Yukinori Ozaki ◽  
Tetsuyo Maeda ◽  
...  

Abstract Background Trastuzumab emtansine (T-DM1) treatment for human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer after taxane with trastuzumab and pertuzumab is standard therapy. However, treatment strategies beyond T-DM1 are still in development with insufficient evidence of their effectiveness. Here, we aimed to evaluate real-world treatment choice and efficacy of treatments after T-DM1 for HER2-positive metastatic breast cancer. Methods In this multi-centre retrospective cohort study involving 17 hospitals, 325 female HER2-positive metastatic breast cancer patients whose post-T-DM1 treatment began between April 15, 2014 and December 31, 2018 were enrolled. The primary end point was the objective response rate (ORR) of post-T-DM1 treatments. Secondary end points included disease control rate (DCR), progression-free survival (PFS), time to treatment failure (TTF), and overall survival (OS). Results The median number of prior treatments of post-T-DM1 treatment was four. The types of post-T-DM1 treatments included (1) chemotherapy in combination with trastuzumab and pertuzumab (n = 102; 31.4%), (2) chemotherapy concomitant with trastuzumab (n = 78; 24.0%), (3), lapatinib with capecitabine (n = 63; 19.4%), and (4) others (n = 82; 25.2%). ORR was 22.8% [95% confidence interval (CI): 18.1–28.0], DCR = 66.6% (95% CI 60.8–72.0), median PFS = 6.1 months (95% CI 5.3–6.7), median TTF = 5.1 months (95% CI 4.4–5.6), and median OS = 23.7 months (95% CI 20.7–27.4). Conclusion The benefits of treatments after T-DM1 are limited. Further investigation of new treatment strategies beyond T-DM1 is awaited for HER2-positive metastatic breast cancer patients.


Sign in / Sign up

Export Citation Format

Share Document